Relay Therapeutics, Inc. - Common Stock — Cash Flow (NASDAQ:RLAY) | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

Quarterly Annual

Cash from operating activities -102.49 M-74.41 M-229.49 M-300.32 M-249.11 M-235.46 M -212.21 M Cash from investing activities 81.67 M-479.51 M-188.75 M257.63 M-41.08 M192.8 M -244.94 M Cash from financing activities 426.51 M388.09 M289.91 M34.75 M270.15 M1.6 M 463.47 M Free cash flow -102.49 M-74.41 M-229.49 M-300.32 M-249.11 M-235.87 M -212.21 M

News

This 'Dynamo' Biotech Puts AI-Fueled Breakout In Motion

The Zacks Analyst Blog Highlights Recursion Pharmaceuticals, Schrodinger, Relay Therapeutics and Absci

4 AI-Powered Drug Discovery Stocks to Watch as AI Reshapes Pharma

Relay Therapeutics Stock Is Up Nearly 500% Over the Past Year

Relay Therapeutics, Inc. (RLAY) Reports Q2 Loss, Lags Revenue Estimates

Akebia Therapeutics (AKBA) Reports Q2 Loss, Lags Revenue Estimates

Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Beats Q1 Earnings Estimates

Relay Therapeutics: Revitalized By Breast Cancer Program, But Competition Is Intense

Relay Therapeutics, Inc. (RLAY) Expected to Beat Earnings Estimates: Should You Buy?

Celcuity: 'Buy' REVTORPYK FDA Approval First And sNDA Label Expansion Q3 2026 (CELC)

Biotech Is The Rate Cut Trade In Disguise

Absci: Eli Lilly Backs Alopecia Data With Funding, But Risks Remain (NASDAQ:ABSI)